OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Vorinostat is currently being evaluated in clinical trials in a shock and kill approach to cure HIV. Transcriptomic and proteomic profiling of Vorinostat in primary CD4 T cells has identified noteworthy off-target effects, subject-to-subject variation, as well as biomarkers that may be monitored to confirm compound exposure.
